Remove Immune Response Remove Presentation Remove Treatment
article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. The presence of p95HER2 – a shortened version of the receptor that still drives tumour growth – makes treatment even more difficult.

article thumbnail

Targeting CD40 with bispecifics to outsmart tumours

Drug Target Review

However, despite impressive advancements, many patients still do not respond to current immunotherapy treatments. This is partly because cancer cells are shrewd and often develop ways to evade immune detection. Prior attempts to target CD40 have been limited to varying degrees by unwanted immune activation causing side effects.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. Preclinical studies have demonstrated potent and selective modulation of the immune response, which plays a crucial role in various inflammatory conditions.

article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

Immuno-oncology has transformed cancer treatment, but for many patients, tumours remain resistant to even the most advanced immune checkpoint inhibitors. These CCR8+ Tregs are known to suppress immune responses in the tumour microenvironment (TME), allowing cancers to grow unchecked.

article thumbnail

Aleta’s Novel T Cell Engagers

SugarCone Biotech

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Other mechanisms that cancer cells use to escape from TCE treatment are less expected. Today, however, we turn to the TCE therapeutic class.

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.